PHARMACEUTICAL giants Boehringer Ingelheim and Lilly have jointly announced that their new oral, fixed-dose combination of the SGLT2 inhibitor empagliflozin (Jardiance) and DPP-4 inhibitor linagliptin (Trajenta) will be available on the Pharmaceutical Benefits Scheme from 01 Apr 2018 as Glyxambi under specific conditions.
Approved PI for Glyxambi can be found at guildlink.com.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Mar 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Mar 18